Why the study?
Hypertriglyceridemia is common yet underappreciated and independently associated with ASCVD risk and pancreatitis, but few guidelines have provided management recommendations.
This document provides practical guidance for the management of hypertriglyceridemia in Egypt to reduce ASCVD and pancreatitis risk.
Provides practical HTG guidance for Egyptian clinicians to reduce ASCVD and pancreatitis risk; extends international data with region-specific, accessible updates.
Hypertriglyceridemia (HTG) is a very common, yet underappreciated problem in clinical practice. Elevated triglyceride (TG) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD) risk. Furthermore, severe HTG may lead to acute pancreatitis. Although LDL-guided statin therapy has improved ASCVD outcomes, residual risk remains. Recent trials have demonstrated that management of high TG levels, in patients already on statin therapy, reduces the rate of major vascular events. Few guidelines were issued, providing important recommendations for HTG management strategies. The goal of treatment is to reduce the risk of ASCVD and acute pancreatitis. The management stands on lifestyle modification, detection of secondary causes of HTG and pharmacological therapy, when indicated. In this guidance we review the causes and classification of HTG and summarize the current methods for risk estimation, diagnosis and treatment. The present guidance provides a focused update on the management of HTG, outlined in a simple user-friendly format, with an emphasis on the latest available data.
No takes yet. Share an insight, caveat, or question.
Taha et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: